Teva Pharms Inc Company Profile
What is the competitive landscape for TEVA PHARMS INC
TEVA PHARMS INC has sixteen approved drugs.
There is one US patent protecting TEVA PHARMS INC drugs. There are three tentative approvals on TEVA PHARMS INC drugs.
Summary for Teva Pharms Inc
| US Patents: | 1 |
| Tradenames: | 16 |
| Ingredients: | 16 |
| NDAs: | 16 |
Drugs and US Patents for Teva Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 220276-004 | Nov 13, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | PRUCALOPRIDE SUCCINATE | prucalopride succinate | TABLET;ORAL | 219071-001 | Feb 5, 2026 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Teva Pharms Inc | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 219686-002 | Jan 22, 2026 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Teva Pharms Inc | THEOPHYLLINE | theophylline | TABLET, EXTENDED RELEASE;ORAL | 216961-001 | Oct 12, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | THEOPHYLLINE | theophylline | TABLET, EXTENDED RELEASE;ORAL | 216961-002 | Oct 12, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | TIOPRONIN | tiopronin | TABLET, DELAYED RELEASE;ORAL | 216456-002 | Jul 22, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Teva Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3692021 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1214076 | SZ 49/2008 | Austria | ⤷ Start Trial | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON |
| 1214076 | C01214076/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 1453521 | 93156 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| 2059246 | 301308 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EEN COMBINATIE VAN (A) MACITENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN (B) TADALAFIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1859 20240930 |
| 0771217 | 07C0001 | France | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
| 1534390 | C20100006 00032 | Estonia | ⤷ Start Trial | PRODUCT NAME: REVOLADE-ELTROMBOPAG; REG NO/DATE: C(2010)1662 11.03.2010 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
